Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Carboplatin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    804 result(s) found for: Carboplatin. Displaying page 1 of 41.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-001428-23 Sponsor Protocol Number: M17GEL Start Date*: 2017-09-29
    Sponsor Name:NKI-AVL
    Full Title: AssessinG Efficacy of carboplatin and ATezOlizumab in metastatic Lobular breast cancer: GELATO-trial
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10024745 Lobular breast carcinoma invasive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000234-33 Sponsor Protocol Number: PKCARBOB Start Date*: 2014-09-30
    Sponsor Name:rijnstate hospital, the netherlands
    Full Title: PHARMACOKINETICS OF CARBOPLATIN AFTER ADJUSTED DOSING FOR HIGH BMI, LOW SERUM CREATININE, AND MAXIMAL RENAL FUNCTION
    Medical condition: non-small cell lung cancer, small cell lung cancer, ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001421-13 Sponsor Protocol Number: AGMT_MBC-10(X16087) Start Date*: 2016-08-31
    Sponsor Name:AGMT gGmbH
    Full Title: Ixazomib (MLN9708) in combination with carboplatin in pretreated women with advanced triple negative breast cancer (CARIXA)
    Medical condition: Advanced (locally advanced inoperable or metastatic) triple negative breast cancer progressing after first-line therapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002399-40 Sponsor Protocol Number: Start Date*: 2005-05-11
    Sponsor Name:Rigshospitalet
    Full Title: Carboplatin + paclitaxel vs carboplatin + stealth liposomal doxorubicin. A randomised multicentre trial.
    Medical condition: Recurrent ovarian cancer Cytologic / histologic diagnosis of stage IC-IV ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005100-34 Sponsor Protocol Number: VX13-970-002 Start Date*: 2014-04-16
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX-970 as a Single Agent in Combination With Carboplatin in Subjects With Advanced Solid Tumors
    Medical condition: Cancer (malignant solid tumors)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000826-24 Sponsor Protocol Number: INCMGA0012-303 Start Date*: 2020-10-29
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carc...
    Medical condition: Male and female participants at least 18 years of age who have inoperable locally recurrent or metastatic Squamous Carcinoma of the Anal Canal (SCAC) not previously treated with systemic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10002127 Anal canal cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) GB (GB - no longer in EU/EEA) NO (Ongoing) DE (Ongoing) FR (Ongoing) DK (Trial now transitioned) IT (Ongoing) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001094-15 Sponsor Protocol Number: CDBC1 Start Date*: 2006-09-04
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust (Cancer Research UK Medical Oncology Unit, Churchill Hospital)
    Full Title: Dose-banding of carboplatin: Effect on area under the plasma concentration - time curve (AUC) compared with individualised dosing
    Medical condition: Conditions for which carboplatin is indicated for: 1. Advanced ovarian carcinoma of epithelial origin in: - first line therapy - second line therapy, after other treatments have failed. 2. Small ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002223-14 Sponsor Protocol Number: MPM2005 Start Date*: 2005-08-25
    Sponsor Name:Rigshospitalet
    Full Title: Fase II study of carboplatin and vinorelbine in malignant pleural mesothelioma
    Medical condition: Patients with malignant pleural mesothelioma who cannot be operated
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001576-12 Sponsor Protocol Number: SGI-110-02 Start Date*: 2013-07-22
    Sponsor Name:Astex Pharmaceuticals Inc
    Full Title: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer
    Medical condition: Platinum-Resistant Recurrent Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004574-11 Sponsor Protocol Number: CS1008-A-E202 Start Date*: 2009-05-26
    Sponsor Name:Daiichi Sankyo Development Limited
    Full Title: RANDOMISED, DOUBLE-BLINDED, PLACEBO- CONTROLLED PHASE 2 STUDY OF CS-1008 IN COMBINATION WITH CARBOPLATIN/PACLITAXEL IN CHEMOTHERAPY NAÏVE SUBJECTS WITH METASTATIC OR UNRESECTABLE NON-SMALL CELL LU...
    Medical condition: Treatment of metastatic or unresectable non small cell lung cancer (NSCLC) with CS 1008 or placebo first in combination with carboplatin/paclitaxel then as monotherapy in the first line setting
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005491-28 Sponsor Protocol Number: MO29594 Start Date*: 2015-06-19
    Sponsor Name:Roche Farma, S.A en nombre de F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTRE OPEN-LABEL SINGLE-ARM PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH METASTATIC, RECURRENT OR PERSIST...
    Medical condition: Metastatic, Recurrent or Persistent Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10008236 Cervical cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) PT (Completed) PL (Completed) GR (Completed) FR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003040-20 Sponsor Protocol Number: MX39795 Start Date*: 2018-06-20
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemoth...
    Medical condition: Cancer of Unknown Primary Site
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10032248 Other malignant neoplasm of unspecified site LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Ongoing) EE (Completed) IE (Completed) DE (Temporarily Halted) CZ (Ongoing) FI (Ongoing) LV (Completed) HU (Ongoing) PL (Completed) FR (Ongoing) ES (Ongoing) BG (Ongoing) PT (Ongoing) HR (Ongoing) NL (Ongoing) DK (Completed) CY (Prematurely Ended) IT (Ongoing) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-003174-18 Sponsor Protocol Number: PACET-CUP Start Date*: 2009-12-18
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated ...
    Medical condition: adeno- and undifferentiated Carcinoma of Unknown Primary (CUP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006068-12 Sponsor Protocol Number: D4320C00036 Start Date*: 2009-08-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian C...
    Medical condition: Patients with advanced ovarian cancer who have relapsed following first-line platinum containing therapy (Patients may have received any other chemotherapy agent with the platinum agent). Relapse m...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003104-12 Sponsor Protocol Number: M19VLC Start Date*: 2020-01-14
    Sponsor Name:NKI-AVL
    Full Title: Treatment of locally advanced VULvar CArcinoma in a Neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy
    Medical condition: vulvar carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001197-28 Sponsor Protocol Number: 201900180 Start Date*: 2019-07-31
    Sponsor Name:University Medical Center Groningen
    Full Title: Can 89Zr-atezolizumab PET scan identify patients with metastatic invasive lobular breast cancer who will respond to chemotherapy-immune checkpoint inhibition?
    Medical condition: Lobular metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003129-27 Sponsor Protocol Number: CBKM120E2102 Start Date*: 2014-02-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM)
    Medical condition: recurrent glioblastoma multiform
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005325-30 Sponsor Protocol Number: D8180C00015 Start Date*: 2008-04-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-Blind, Placebo Controlled, Multi-Centre, Randomised Study of AZD0530 in Patients with Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy
    Medical condition: advanced ovarian cancer sensitive to platinum based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033129 Ovarian neoplasms malignant (excl germ cell) HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) FR (Completed) DK (Completed) PT (Completed) BG (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000722-69 Sponsor Protocol Number: GEICO-0104 Start Date*: 2004-11-25
    Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario (GEICO)
    Full Title: A PHASE II, RANDOMIZED STUDY OF CARBOPLATIN-GEMCITABINE PLUS CARBOPLATIN-PACLITAXEL VERSUS CARBOPLATIN-PACLITAXEL IN PLATINUM-SENSITIVE PATIENTS WITH RECURRENT OVARIAN CARCINOMA, PRIMARY PERITONEAL...
    Medical condition: Ovarian Carcinoma (MedDRA 6.1, PT:10033128), Primary Peritoneal Carcinoma (MedDRA 6.1, PT:10052171) and Fallopian Tube Cancer (MedDRA 6.1, PT:10016180),
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033128 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019106-16 Sponsor Protocol Number: MK-1775009 Start Date*: 2010-05-31
    Sponsor Name:Netherlands Cancer Institute (NKI)
    Full Title: Phase II and Pharmacological Study with Wee-1 Inhibitor AZD1775 Combined with Carboplatin in Patients with p53 Mutated Epithelial Ovarian Cancer that Show Early Relapse (< 3 months) or Progressio...
    Medical condition: p53 mutated epithelial ovarian cancer (after first line standard therapy), non-small cell lung cancer, small cell lung cancer, cervical and endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055094 Cervix cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA